EU IVDR Performance Studies under Article 58: Interventional Studies and Annex XIV

1. Key takeaways

Article 58 imposes additional requirements for certain performance studies on top of the general requirements of Article 57. It targets primarily interventional clinical performance studies and other performance studies that pose a risk to the subjects, with the specific requirements set out in Annex XIV. The relationship between the two provisions is one of layering: Article 57 is the floor that applies to every performance study, and Article 58 only adds obligations on top of it; it does not replace the baseline.

For sponsors, the practical question is therefore not whether Article 57 applies, since it always does, but whether the study crosses into the scope of Article 58. Answering that question early determines the size of the document package, the involvement of the person responsible for regulatory compliance, and the depth of subject protection arrangements that the protocol must carry.

2. Legal basis

3. Expert insights

Insight 1: The starting point of the assessment is whether the study changes clinical management decisions.

The defining feature of an interventional clinical performance study is that the study results affect the clinical management of the subject, rather than merely serving to assess the performance of the device. Because the results influence decisions about the subject, the study poses an additional risk to that subject, and it is precisely this situation that Article 58 and Annex XIV address. Studies that only use left-over samples and do not alter clinical decision-making typically fall outside the scope of Article 58. The determination should be documented at the study design stage, describing why the results will or will not influence clinical management, because that reasoning is what ethics committees, Member State assessors and auditors will ask for first.

Insight 2: Articles 59 to 65 form the subject protection cluster that accompanies Article 58.

Article 59 on informed consent, Article 60 on incapacitated subjects, Article 61 on minors, Article 62 on pregnant or breastfeeding women, Article 63 on national measures, Article 64 on studies performed in emergency situations and Article 65 on damages together make up the statutory subject protection list. For a study within the scope of Article 58, the protocol and the informed consent documents must be checked line by line against these provisions: how consent is obtained and documented, what applies when a subject cannot consent, what extra safeguards apply for minors and for pregnant or breastfeeding women, what national additional measures exist in each participating country, and how the damage compensation obligation is covered. This cluster is not optional reading; it is the checklist against which the study documents are judged.

Insight 3: One statutory duty of the PRRC lands precisely here.

Article 15(3)(e) lists, among the minimum tasks of the person responsible for regulatory compliance (PRRC), the issuance of the statement required by Section 4.1 of Annex XIV for interventional clinical performance studies or other performance studies posing a risk to the subjects. Without the written statement of the PRRC, the compliance chain of such a study is broken: the application file is incomplete and the study cannot be defended in an audit. Organisations should therefore verify that the PRRC role is filled, that the person is involved early enough to review the study design, and that the statement is generated, signed and archived as part of the study master file for every qualifying study.

Insight 4: Article 76 institutionalises the recording and reporting of adverse events during the study.

Article 76 requires the recording and reporting of adverse events that occur during a performance study. It is a separate mechanism from the post-market vigilance reporting under Article 82: the subjects differ, the reporting routes differ and the forms differ. However, the underlying data sources can be managed in a unified way inside the organisation, with one adverse event definition and one capture system feeding both the study reporting pathway and the post-market pathway. Sponsors should map these two routes explicitly in their quality system, because mixing them up, for example sending a study adverse event through the post-market route, creates reporting gaps that are difficult to reconstruct afterwards.

4. Practical recommendations

1. Perform an Article 58 applicability determination at the study initiation stage: whether the study is interventional and whether its results affect clinical management decisions, and record the reasoning.
2. Where Article 58 applies, build the document package in line with Annex XIV and break Articles 59 to 65 down into an item-by-item checklist applied to the protocol and the informed consent documents.
3. Have the PRRC issue the statement required by Annex XIV Section 4.1 and archive it in the study master file under Article 15(3)(e).
4. Establish a recording and reporting process for adverse events during the study under Article 76, kept distinct from the post-market vigilance process but sharing the same data source and definitions.
5. Prepare the application and Member State assessment materials of Articles 66 and 67 to the standard expected for interventional studies; as a practical estimate, plan the assessment cycle in quarters.

5. Verification checklist

• □ The Article 58 applicability determination has been completed, covering interventional character and influence on clinical decisions
• □ The Annex XIV document package has been established
• □ The subject protection requirements of Articles 59 to 65 have been implemented item by item in the informed consent documents and the protocol
• □ The PRRC has issued the statement required by Annex XIV Section 4.1 under Article 15(3)(e)
• □ A recording and reporting process for adverse events during the study has been established under Article 76
• □ The application and assessment timelines of Articles 66 and 67 are included in the project plan

GRZAN supports manufacturers entering or operating in the EU in vitro diagnostic market with performance study compliance under the IVDR: Article 58 applicability determinations, Annex XIV document packages, subject protection mapping of Articles 59 to 65, PRRC statements under Section 4.1 and adverse event reporting processes under Article 76. Contact us at info@grzanglobal.com for support with interventional clinical performance studies.

Legal information verified as of 29 October 2026.